```
     FILE 'REGISTRY' ENTERED AT 09:34:28 ON 17 OCT 2008
L1                STRUCTURE UPLOADED
L2              1 S L1
L3              3 S L1 FAM FULL

     FILE 'HCAPLUS' ENTERED AT 09:36:20 ON 17 OCT 2008
L4            109 S L3
L5            404 S (COMPLEX REGIONAL PAIN) OR (REFLEX SYMPATHETIC DYSTROPHY)
L6              3 S L4 AND L5
L7          63458 S PAIN
L8              5 S L4 AND L7
L9              2 S L8 NOT L6

     FILE 'REGISTRY' ENTERED AT 09:51:23 ON 17 OCT 2008
L10               STRUCTURE UPLOADED
L11             0 S L10
L12             7 S L10 FAM FULL

     FILE 'HCAPLUS' ENTERED AT 09:52:02 ON 17 OCT 2008
L13           464 S L12
L14             3 S L5 AND L13
L15            17 S L7 AND L13
L16             7 S L15 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.84       0.84

FILE 'REGISTRY' ENTERED AT 09:34:28 ON 17 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 OCT 2008  HIGHEST RN 1061881-29-5
DICTIONARY FILE UPDATES:  15 OCT 2008  HIGHEST RN 1061881-29-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10693794specific.str
```



```
chain nodes :
10  11  12  13  14  15  16  17  24  25  26
ring nodes :
1  2  3  4  5  6  7  8  9  18  19  20  21  22  23
chain bonds :
1-10  2-15  3-14  4-13  7-12  8-18  9-11  10-16  10-17  19-24  20-26  21-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  18-19  18-23  19-20  20-21  21-22
22-23
exact/norm bonds :
1-10  5-7  6-9  7-8  7-12  8-9  8-18  9-11  18-19  18-23  19-20  19-24  20-21  21-22
21-25  22-23
exact bonds :
2-15  3-14  4-13  10-16  10-17  20-26
```

```
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:Atom
19:Atom  20:Atom  21:Atom
22:Atom  23:Atom  24:CLASS  25:CLASS  26:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 09:34:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      105 TO ITERATE

100.0% PROCESSED      105 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1486 TO     2714
PROJECTED ANSWERS:                1 TO       80

L2            1 SEA SSS SAM L1

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> d l2 scan


L2   1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   1H-Isoindole-1,3(2H)-dione, 4-amino-2-[(3R)-3-methyl-2,6-dioxo-3-
     piperidinyl]-
MF   C14 H13 N3 O4
```

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 fam full
FULL SEARCH INITIATED 09:36:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   357 TO ITERATE

100.0% PROCESSED   357 ITERATIONS   3 ANSWERS
SEARCH TIME: 00.00.01

L3   3 SEA FAM FUL L1

=> d l3 scan

L3   3 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   1H-Isoindole-1,3(2H)-dione, 4-amino-2-[(3R)-2,6-dioxo-3-piperidinyl]-
MF   C13 H11 N3 O4

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-
MF C13 H11 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-[(3S)-2,6-dioxo-3-piperidinyl]-
MF C13 H11 N3 O4

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 71.03 TOTAL SESSION 71.87

FULL ESTIMATED COST 71.03 71.87

FILE 'HCAPLUS' ENTERED AT 09:36:20 ON 17 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 17 Oct 2008 VOL 149 ISS 17
FILE LAST UPDATED: 16 Oct 2008 (20081016/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 109 L3

=> s (complex regional pain) or (reflex sympathetic dystrophy)
1440940 COMPLEX
74319 REGIONAL
63458 PAIN
208 COMPLEX REGIONAL PAIN
(COMPLEX(W)REGIONAL(W)PAIN)
26747 REFLEX
41731 SYMPATHETIC
14470 DYSTROPHY
226 REFLEX SYMPATHETIC DYSTROPHY
(REFLEX(W)SYMPATHETIC(W)DYSTROPHY)
L5 404 (COMPLEX REGIONAL PAIN) OR (REFLEX SYMPATHETIC DYSTROPHY)

=> s l4 and l5
L6 3 L4 AND L5

=> d l6 1-3 ti abs bib

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
AB Methods are disclosed for treating, preventing and/or managing dysfunctional sleep, including but not limited to, dysfunctional sleep associated with chronic neurol. or inflammatory condition such as pain and neurodegenerative disorders, which comprise the administration of one or more immunomodulatory compds. or a pharmaceutically acceptable salt, solvate, stereoisomer, clathrate or prodrug thereof, alone or in combination with known therapeutics. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. Immunomodulatory compds. include e.g. 4-amino-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione.
AN 2005:1078258 HCAPLUS <<LOGINID::20081017>>
DN 143:339698
TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
IN Zeldis, Jerome B.; Manning, Donald C.; Faleck, Herbert
PA USA
SO U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 20050222209	A1	20051006	US 2005-93848	20050330
	AU 2005231415	A1	20051020	AU 2005-231415	20050331
	CA 2561910	A1	20051020	CA 2005-2561910	20050331
	WO 2005097125	A2	20051020	WO 2005-US10937	20050331
	WO 2005097125	A3	20070125		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1740178	A2	20070110	EP 2005-731426	20050331
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1980667	A	20070613	CN 2005-80017546	20050331
	BR 2005009400	A	20070828	BR 2005-9400	20050331
	JP 2007531770	T	20071108	JP 2007-506569	20050331
	MX 2006PA11216	A	20070116	MX 2006-PA11216	20060929
	KR 2007007880	A	20070116	KR 2006-722827	20061031
PRAI	US 2004-559261P	P	20040401		
	WO 2005-US10937	W	20050331		

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain

AB Methods for treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2005:426405 HCAPLUS <<LOGINID::20081017>>

DN 142:457122

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain

IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.

PA Celgene Corporation, USA

SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044178	A2	20050519	WO 2004-US12721	20040423
	WO 2005044178	A3	20051027		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 20050203142	A1	20050915	US 2003-693794	20031023
	AU 2004286818	A1	20050519	AU 2004-286818	20040423
	CA 2543160	A1	20050519	CA 2004-2543160	20040423
	EP 1680111	A2	20060719	EP 2004-750612	20040423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004015007	A	20061107	BR 2004-15007	20040423
	CN 1897945	A	20070117	CN 2004-80038171	20040423
	JP 2007525484	T	20070906	JP 2006-536542	20040423
	MX 2006PA04427	A	20060627	MX 2006-PA4427	20060421
	IN 2006CN01805	A	20070608	IN 2006-CN1805	20060523
	US 20070244078	A1	20071018	US 2007-576152	20070213
PRAI	US 2003-693794	A	20031023		
	US 2002-421003P	P	20021024		
	WO 2004-US12721	W	20040423		

OS MARPAT 142:457122

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

GI



I

AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:368888 HCAPLUS <<LOGINID::20081017>>

DN 140:368712

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.

PA Celgene Corporation, USA

SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037199	A2	20040506	WO 2003-US33757	20031024
	WO 2004037199	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

```
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2503536          A1    20040506    CA 2003-2503536         20031024
    AU 2003286663       A1    20040513    AU 2003-286663          20031024
    EP 1556044          A2    20050727    EP 2003-777871          20031024
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003015609       A     20050823    BR 2003-15609           20031024
    CN 1732000          A     20060208    CN 2003-80107531        20031024
    CN 1326522          C     20070718
    JP 2006507284       T     20060302    JP 2004-547126          20031024
    CN 101108185        A     20080123    CN 2007-10103924        20031024
    MX 2005PA04182      A     20050608    MX 2005-PA4182          20050420
    HK 1088225          A1    20080222    HK 2006-108551          20060801
PRAI US 2002-421003P    P     20021024
    CN 2003-80107531    A3    20031024
    WO 2003-US33757     W     20031024
OS  MARPAT 140:368712


=> s pain
L7       63458 PAIN

=> s l4 and l7
L8           5 L4 AND L7

=> d l8 not l6
L6 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l8 not l6
L9           2 L8 NOT L6

=> d l9 1-2 ti abs bib

L9   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method of using, and compositions comprising, immunomodulatory compounds
     for the treatment and management of myeloproliferative diseases
AB   Methods of treating, preventing, and/or managing a myeloproliferative
     disease are disclosed.  Specific methods encompass the administration of
     an immunomodulatory compound, or a pharmaceutically acceptable salt,
     solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in
     combination with a second active agent, and/or the transplantation of
     blood or cells.  Particular second active agents are capable of
     suppressing the overprodn. of hematopoietic stem cells or ameliorating one
     or more of the symptoms of a myeloproliferative disease.  Pharmaceutical
     compns., single unit dosage forms, and kits suitable for use in methods of
     the invention are also disclosed.
AN   2005:1259339  HCAPLUS <<LOGINID::20081017>>
DN   144:17165
TI   Method of using, and compositions comprising, immunomodulatory compounds
     for the treatment and management of myeloproliferative diseases
IN   Zeldis, Jerome B.
PA   Celgene Corporation, USA
SO   PCT Int. Appl., 59 pp.
```

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005112928	A1	20051201	WO 2004-US14003	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004319816	A1	20051201	AU 2004-319816	20040505
CA 2565447	A1	20051201	CA 2004-2565447	20040505
EP 1746995	A1	20070131	EP 2004-751399	20040505
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
CN 1984657	A	20070620	CN 2004-80043535	20040505
BR 2004018798	A	20071016	BR 2004-18798	20040505
JP 2007536223	T	20071213	JP 2007-511329	20040505
MX 2006PA12648	A	20070214	MX 2006-PA12648	20061101
KR 2007019754	A	20070215	KR 2006-725518	20061204
PRAI WO 2004-US14003	A	20040505		

OS MARPAT 144:17165
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
AB Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overprodn. of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. The immunomodulatory compound is especially 4-(amino)-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione or 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione.
AN 2004:372856 HCAPLUS <<LOGINID::20081017>>
DN 140:368680
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
IN Zeldis, Jerome B.
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   US 20040087546       A1    20040506    US 2003-411656          20030411
     CA 2504663           A1    20040527    CA 2003-2504663         20030413
     WO 2004043464        A1    20040527    WO 2003-US11328         20030413
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003241289        A1    20040603    AU 2003-241289          20030413
     AU 2003241289        B2    20080103
     EP 1567157           A1    20050831    EP 2003-731018          20030413
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016082        A     20050927    BR 2003-16082           20030413
     CN 1720045           A     20060111    CN 2003-825761          20030413
     JP 2006507325        T     20060302    JP 2004-551395          20030413
     ZA 2005003666        A     20060830    ZA 2005-3666            20030413
     NZ 540382            A     20080530    NZ 2003-540382          20030413
     MX 2005PA04778       A     20051005    MX 2005-PA4778          20050504
     US 20060166932       A1    20060727    US 2006-371777          20060308
PRAI US 2002-424730P      P     20021106
     US 2003-411656       A3    20030411
     WO 2003-US11328      W     20030413
OS   MARPAT 140:368680


=> d his

     (FILE 'HOME' ENTERED AT 09:31:58 ON 17 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 09:34:28 ON 17 OCT 2008
L1             STRUCTURE UPLOADED
L2               1 S L1
L3               3 S L1 FAM FULL

     FILE 'HCAPLUS' ENTERED AT 09:36:20 ON 17 OCT 2008
L4             109 S L3
L5             404 S (COMPLEX REGIONAL PAIN) OR (REFLEX SYMPATHETIC DYSTROPHY)
L6               3 S L4 AND L5
L7           63458 S PAIN
L8               5 S L4 AND L7
L9               2 S L8 NOT L6

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   19.93      91.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -4.00      -4.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:37:44 ON 17 OCT 2008

Connecting via Winsock to STN
```

```
Welcome to STN International!  Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 09:51:04 ON 17 OCT 2008
FILE 'HCAPLUS' ENTERED AT 09:51:04 ON 17 OCT 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      19.93      91.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.00      -4.00

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      22.62      94.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.00      -4.00

FILE 'REGISTRY' ENTERED AT 09:51:23 ON 17 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 OCT 2008  HIGHEST RN 1061881-29-5
DICTIONARY FILE UPDATES:  15 OCT 2008  HIGHEST RN 1061881-29-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10693794specific2.str
```



chain nodes :
10 11 12 13 14 15 16 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22
chain bonds :
1-10 2-14 3-13 4-12 7-11 8-17 10-15 10-16 18-23 19-25 20-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22
exact/norm bonds :
1-10 5-7 6-9 7-8 7-11 8-9 8-17 17-18 17-22 18-19 18-23 19-20 20-21
20-24
21-22
exact bonds :
2-14 3-13 4-12 10-15 10-16 19-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom
22:Atom 23:CLASS 24:CLASS 25:CLASS

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l10
SAMPLE SEARCH INITIATED 09:51:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      105 TO ITERATE

100.0% PROCESSED      105 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1486 TO     2714
PROJECTED ANSWERS:               0 TO        0

L11           0 SEA SSS SAM L10

=> s l10 fam full
FULL SEARCH INITIATED 09:51:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      293 TO ITERATE

100.0% PROCESSED      293 ITERATIONS                                7 ANSWERS
SEARCH TIME: 00.00.01

L12           7 SEA FAM FUL L10

=> d l12 scan

L12  7 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
     hydrate (1:2)
MF   C13 H13 N3 O3 . 2 H2 O
```



●2 H_2O

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L12 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (+)-
MF C13 H13 N3 O3

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-
MF C13 H13 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, hydrate (2:1)
MF C13 H13 N3 O3 . 1/2 H2 O



●1/2 H_2O

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	70.11	164.60
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

FILE 'HCAPLUS' ENTERED AT 09:52:02 ON 17 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Oct 2008 VOL 149 ISS 17
FILE LAST UPDATED: 16 Oct 2008 (20081016/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L13 464 L12

=> s l5 and l13

```
L14          3 L5 AND L13

=> s 17 and l13
L15         17 L7 AND L13

=> s l15 and (PY<2003 or AY<2003 or PRY<2003)
      2295905 PY<2003
       449839 AY<2003
       396698 PRY<2003
L16          7 L15 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l16 1-7 ti abs bib

L16  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Methods of using and compositions comprising immunomodulatory compounds
     for treatment, modification, and management of pain
AB   Methods for treating, preventing, modifying and managing various types of
     pain are disclosed.  Specific methods comprise the administration
     of an immunomodulatory compound, or a pharmaceutically acceptable salt,
     solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in
     combination with a second active agent and/or surgery, psychol. or phys.
     therapy.  Pharmaceutical compns., single unit dosage forms, and kits
     suitable for use in methods of the invention are also disclosed.
AN   2005:426405  HCAPLUS <<LOGINID::20081017>>
DN   142:457122
TI   Methods of using and compositions comprising immunomodulatory compounds
     for treatment, modification, and management of pain
IN   Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.
PA   Celgene Corporation, USA
SO   PCT Int. Appl., 62 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2005044178       A2     20050519    WO 2004-US12721        20040423
     WO 2005044178       A3     20051027
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
              BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
              ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
              SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
              TD, TG
     US 20050203142       A1     20050915    US 2003-693794         20031023 <--
     AU 2004286818        A1     20050519    AU 2004-286818         20040423
     CA 2543160           A1     20050519    CA 2004-2543160        20040423
     EP 1680111           A2     20060719    EP 2004-750612         20040423
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     BR 2004015007        A      20061107    BR 2004-15007          20040423
     CN 1897945           A      20070117    CN 2004-80038171       20040423
     JP 2007525484        T      20070906    JP 2006-536542         20040423
     MX 2006PA04427       A      20060627    MX 2006-PA4427         20060421
     IN 2006CN01805       A      20070608    IN 2006-CN1805         20060523
     US 20070244078       A1     20071018    US 2007-576152         20070213
```

```
PRAI US 2003-693794       A     20031023
    US 2002-421003P       P     20021024  <--
    WO 2004-US12721       W     20040423
OS  MARPAT 142:457122

L16 ANSWER 2 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  Methods of using and compositions comprising immunomodulatory compounds
    for the treatment and management of myeloproliferative diseases
AB  Methods of treating, preventing and/or managing a myeloproliferative
    disease are disclosed.  Specific methods encompass the administration of
    an immunomodulatory compound, or a pharmaceutically acceptable salt,
    solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in
    combination with a second active agent, and/or the transplantation of
    blood or cells.  Particular second active agents are capable of
    suppressing the overprodn. of hematopoietic stem cells or ameliorating one
    or more of the symptoms of a myeloproliferative disease.  Pharmaceutical
    compns., single unit dosage forms, and kits suitable for use in methods of
    the invention are also disclosed.  The immunomodulatory compound is especially
    4-(amino)-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione or
    3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione.
AN  2004:372856  HCAPLUS <<LOGINID::20081017>>
DN  140:368680
TI  Methods of using and compositions comprising immunomodulatory compounds
    for the treatment and management of myeloproliferative diseases
IN  Zeldis, Jerome B.
PA  USA
SO  U.S. Pat. Appl. Publ., 20 pp.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
    ---------------     ----   --------    --------------------   --------
PI  US 20040087546      A1     20040506    US 2003-411656         20030411 <--
    CA 2504663          A1     20040527    CA 2003-2504663        20030413 <--
    WO 2004043464       A1     20040527    WO 2003-US11328        20030413 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
           PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
           UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
           KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
           FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
           BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003241289       A1     20040603    AU 2003-241289         20030413 <--
    AU 2003241289       B2     20080103
    EP 1567157          A1     20050831    EP 2003-731018         20030413 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003016082       A      20050927    BR 2003-16082          20030413 <--
    CN 1720045          A      20060111    CN 2003-825761         20030413 <--
    JP 2006507325       T      20060302    JP 2004-551395         20030413 <--
    ZA 2005003666       A      20060830    ZA 2005-3666           20030413 <--
    NZ 540382           A      20080530    NZ 2003-540382         20030413 <--
    MX 2005PA04778      A      20051005    MX 2005-PA4778         20050504 <--
    US 20060166932      A1     20060727    US 2006-371777         20060308 <--
PRAI US 2002-424730P    P      20021106  <--
    US 2003-411656      A3     20030411
    WO 2003-US11328     W      20030413
```

OS MARPAT 140:368680

L16 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
GI



I

AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical comps., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:368888 HCAPLUS <<LOGINID::20081017>>
DN 140:368712
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.
PA Celgene Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004037199	A2	20040506	WO 2003-US33757	20031024 <--
WO 2004037199	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503536	A1	20040506	CA 2003-2503536	20031024 <--
AU 2003286663	A1	20040513	AU 2003-286663	20031024 <--
EP 1556044	A2	20050727	EP 2003-777871	20031024 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015609	A	20050823	BR 2003-15609	20031024 <--
CN 1732000	A	20060208	CN 2003-80107531	20031024 <--
CN 1326522	C	20070718		
JP 2006507284	T	20060302	JP 2004-547126	20031024 <--
CN 101108185	A	20080123	CN 2007-10103924	20031024 <--

```
     MX 2005PA04182       A     20050608    MX 2005-PA4182          20050420 <--
     HK 1088225           A1    20080222    HK 2006-108551          20060801 <--
PRAI US 2002-421003P      P     20021024  <--
     CN 2003-80107531     A3    20031024
     WO 2003-US33757      W     20031024
OS   MARPAT 140:368712

L16  ANSWER 4 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Method using dialkyl ethers and other compounds for treating arthritis,
     cartilage damage, and other interleukin 6-mediated conditions
AB   The invention discloses combinations, compns., and methods using or having
     a substituted dialkyl ether, substituted aryl-alkyl ether, substituted
     dialkyl thioether, substituted dialkyl ketone, or substituted alkyl
     compound, or a pharmaceutically acceptable salt thereof, as an active
     component for preventing or treating osteoarthritis, preventing or
     inhibiting cartilage damage, preventing or treating rheumatoid arthritis,
     improving joint function, alleviating pain, including joint
     pain, and the like in a patient in need thereof.  Compds. of the
     invention include e.g. 6-(5-carboxy-5-methyl-hexyloxy)-2,2-
     dimethylhexanoic acid calcium salt (CI-1027).
AN   2004:182691  HCAPLUS <<LOGINID::20081017>>
DN   140:210765
TI   Method using dialkyl ethers and other compounds for treating arthritis,
     cartilage damage, and other interleukin 6-mediated conditions
IN   Cornicelli, Joseph Anthony; Kilgore, Kenneth Stanley; Sliskovic, Drago
     Robert; Bove, Susan Elizabeth; Neideffer, David Herbert; Kowala, Mark
     Charles
PA   Warner-Lambert Company LLC, USA
SO   PCT Int. Appl., 117 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    -------------------     --------
PI   WO 2004017952        A1     20040304    WO 2003-IB3664          20030813 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20040048910        A1     20040311    US 2003-639719          20030812 <--
     CA 2494544            A1     20040304    CA 2003-2494544         20030813 <--
     AU 2003255937         A1     20040311    AU 2003-255937          20030813 <--
     EP 1539127            A1     20050615    EP 2003-792585          20030813 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003013883         A      20050719    BR 2003-13883           20030813 <--
     CN 1678297            A      20051005    CN 2003-819951          20030813 <--
     JP 2006501238         T      20060112    JP 2004-530464          20030813 <--
     MX 2005PA01254        A      20050608    MX 2005-PA1254          20050131 <--
     US 20070203212        A1     20070830    US 2007-738679          20070423 <--
PRAI US 2002-405250P       P      20020822  <--
     US 2003-475443P       P      20030603
     US 2003-477092P       P      20030609
     US 2003-484808P       P      20030703
```

```
     US 2003-639719        A1    20030812
     WO 2003-IB3664        W     20030813
OS   MARPAT 140:210765
RE.CNT  3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 5 OF 7  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Treatment of low back pain and whiplash-associated disorder
     with, for example, a monoclonal antibody, an antisense oligonucleotide, or
     an MMP inhibitor
AB   The use of a substance that inhibits disk-related nerve-irritating
     substances for the production of a pharmaceutical composition for treatment of
low
     back pain and/or whiplash-associated disorder (WAD) is disclosed.
     The substance that inhibits disk-related nerve-irritating substances is,
     e.g., a monoclonal antibody, a soluble cytokine receptor or a receptor
     antagonist, an antisense oligonucleotide, an MMP inhibitor, a quinolone, a
     thalidomide derivative, an inhibitor of IL-1, IL-6, IL-8, or IFN-γ, and
     a nitric oxide or eicosanoid blocking substance.  Also a method for
     treatment of low back pain and/or whiplash-associated disorder
     (WAD) is disclosed.  For example, a male patient diagnosed with sciatica
     due to disk herniation and whiplash-associated disorder (pain in
     the region of the neck that radiated out into both arms after a vehicle
     accident) was treated with an i.v. injection of 2.5 mL of Orthogen (an
     IL-1 receptor antagonist) dissolved in 2.5 mL saline.  The day after the
     injection, the patient reported that the sciatic pain was
     markedly reduced.  His problems in the neck region were also greatly
     improved and minor stiffness in the neck and the radiating pain
     in the arms had more or less disappeared.  At the follow-up examination 1 wk
     later, he reported that he only suffered minor pain in the legs
     and also in the neck.  Four weeks after the injection, the patient
     considered himself free of symptoms, and this was the case also at the
     final follow-up examination at 8 wk.
AN   2002:793397  HCAPLUS <<LOGINID::20081017>>
DN   137:289029
TI   Treatment of low back pain and whiplash-associated disorder
     with, for example, a monoclonal antibody, an antisense oligonucleotide, or
     an MMP inhibitor
IN   Olmarker, Kjell; Rydevik, Bjoern
PA   A+ Science Invest AB, Swed.
SO   PCT Int. Appl., 35 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2002080893        A1    20021017    WO 2002-SE673          20020405 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002249742         A1    20021021    AU 2002-249742         20020405 <--
PRAI SE 2001-1258          A     20010406  <--
     WO 2002-SE673         W     20020405  <--
RE.CNT  9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Use of a TNF inhibitor for the treatment of low back pain
AB The use of a tumor necrosis factor (TNF) inhibitor for the production of a pharmaceutical composition for treatment of low back pain and in particular of low back pain due to local irritation of annulus-related nerve fibers by disk derived substances is described. Also a method for treatment of low back pain is disclosed. For example, a patient was given infliximab, a selective monoclonal antibody that inhibits only TNF, at 5 mg/kg for treatment of low back pain . Approx. 1.5 h after completing the administration the patient started to feel symptoms of relief regarding his pain. The improvement was found to be dramatic at the follow-up examns. and persisted during 4 wk.
AN 2002:793395 HCAPLUS <<LOGINID::20081017>>
DN 137:304790
TI Use of a TNF inhibitor for the treatment of low back pain
IN Olmarker, Kjell; Rydevik, Bjoern
PA A+ Science Invest AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080891	A1	20021017	WO 2002-SE671	20020405 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002249741	A1	20021021	AU 2002-249741	20020405 <--
PRAI	SE 2001-1256	A	20010406	<--	
	WO 2002-SE671	W	20020405	<--	

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Formulations of adenosine A1 agonists
AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and an NSAID, e.g., a COX-2 inhibitor. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol (I) was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection. I and 2-(4-ethoxy-phenyl)-3-(4-methanesulfonylphenyl)pyrazolo[1,5-b]pyridazine(COX-2 inhibitor), were administered at 1% to rats. The compds. showed inhibition of carrageenan-induced edema and allodynia.
AN 2001:472471 HCAPLUS <<LOGINID::20081017>>

DN 135:81971
TI Formulations of adenosine A1 agonists
IN Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001045683	A2	20010628	WO 2000-GB4883	20001219	<--
	WO 2001045683	A3	20020314			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	EP 1239879	A2	20020918	EP 2000-985627	20001219	<--
	EP 1239879	B1	20040225			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2003519104	T	20030617	JP 2001-546422	20001219	<--
	AT 260119	T	20040315	AT 2000-985627	20001219	<--
	US 20030004128	A1	20030102	US 2002-168195	20020618	<--
PRAI	GB 1999-30075	A	19991220	<--		
	WO 2000-GB4883	W	20001219	<--		